دورية أكاديمية
أعرض في EDS

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del).

التفاصيل البيبلوغرافية
العنوان: Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del).
المؤلفون: Heneghan M; Department of Women's and Children's Health, University of Liverpool, Liverpool, UK., Southern KW; Department of Women's and Children's Health, University of Liverpool, Liverpool, UK., Murphy J; Leighton Hospital, Crewe, UK., Sinha IP; Department of Women's and Children's Health, University of Liverpool, Liverpool, UK., Nevitt SJ; Department of Health Data Science, University of Liverpool, Liverpool, UK.; Centre for Reviews and Dissemination, University of York, York, UK.
المصدر: The Cochrane database of systematic reviews [Cochrane Database Syst Rev] 2023 Nov 20; Vol. 11. Cochrane AN: CD010966. Date of Electronic Publication: 2023 Nov 20.
نوع المنشور: Systematic Review; Journal Article; Review; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Wiley Country of Publication: England NLM ID: 100909747 Publication Model: Electronic Cited Medium: Internet ISSN: 1469-493X (Electronic) Linking ISSN: 13616137 NLM ISO Abbreviation: Cochrane Database Syst Rev Subsets: MEDLINE
أسماء مطبوعة: Publication: 2004- : Chichester, West Sussex, England : Wiley
Original Publication: Oxford, U.K. ; Vista, CA : Update Software,
مواضيع طبية MeSH: Cystic Fibrosis*/drug therapy , Cystic Fibrosis*/genetics, Adult ; Child ; Humans ; Cystic Fibrosis Transmembrane Conductance Regulator/genetics ; Aminophenols/adverse effects ; Dyspnea/drug therapy ; Mutation
مستخلص: Background: Cystic fibrosis (CF) is a common life-shortening genetic condition caused by a variant in the cystic fibrosis transmembrane conductance regulator (CFTR) protein. A class II CFTR variant F508del is the commonest CF-causing variant (found in up to 90% of people with CF (pwCF)). The F508del variant lacks meaningful CFTR function - faulty protein is degraded before reaching the cell membrane, where it needs to be to effect transepithelial salt transport. Corrective therapy could benefit many pwCF. This review evaluates single correctors (monotherapy) and any combination of correctors (most commonly lumacaftor, tezacaftor, elexacaftor, VX-659, VX-440 or VX-152) and a potentiator (e.g. ivacaftor) (dual and triple therapies).
Objectives: To evaluate the effects of CFTR correctors (with or without potentiators) on clinically important benefits and harms in pwCF of any age with class II CFTR mutations (most commonly F508del).
Search Methods: We searched the Cochrane CF Trials Register (28 November 2022), reference lists of relevant articles and online trials registries (3 December 2022).
Selection Criteria: Randomised controlled trials (RCTs) (parallel design) comparing CFTR correctors to control in pwCF with class II mutations.
Data Collection and Analysis: Two authors independently extracted data, assessed risk of bias and judged evidence certainty (GRADE); we contacted investigators for additional data.
Main Results: We included 34 RCTs (4781 participants), lasting between 1 day and 48 weeks; an extension of two lumacaftor-ivacaftor studies provided additional 96-week safety data (1029 participants). We assessed eight monotherapy RCTs (344 participants) (4PBA, CPX, lumacaftor, cavosonstat and FDL169), 16 dual-therapy RCTs (2627 participants) (lumacaftor-ivacaftor or tezacaftor-ivacaftor) and 11 triple-therapy RCTs (1804 participants) (elexacaftor-tezacaftor-ivacaftor/deutivacaftor; VX-659-tezacaftor-ivacaftor/deutivacaftor; VX-440-tezacaftor-ivacaftor; VX-152-tezacaftor-ivacaftor). Participants in 21 RCTs had the genotype F508del/F508del, in seven RCTs they had F508del/minimal function (MF), in one RCT F508del/gating genotypes, in one RCT either F508del/F508del genotypes or F508del/residual function genotypes, in one RCT either F508del/gating or F508del/residual function genotypes, and in three RCTs either F508del/F508del genotypes or F508del/MF genotypes. Risk of bias judgements varied across different comparisons. Results from 16 RCTs may not be applicable to all pwCF due to age limits (e.g. adults only) or non-standard designs (converting from monotherapy to combination therapy). Monotherapy Investigators reported no deaths or clinically relevant improvements in quality of life (QoL). There was insufficient evidence to determine effects on lung function. No placebo-controlled monotherapy RCT demonstrated differences in mild, moderate or severe adverse effects (AEs); the clinical relevance of these events is difficult to assess due to their variety and few participants (all F508del/F508del). Dual therapy In a tezacaftor-ivacaftor group there was one death (deemed unrelated to the study drug). QoL scores (respiratory domain) favoured both lumacaftor-ivacaftor and tezacaftor-ivacaftor therapy compared to placebo at all time points (moderate-certainty evidence). At six months, relative change in forced expiratory volume in one second (FEV 1 ) % predicted improved with all dual combination therapies compared to placebo (high- to moderate-certainty evidence). More pwCF reported early transient breathlessness with lumacaftor-ivacaftor (odds ratio (OR) 2.05, 99% confidence interval (CI) 1.10 to 3.83; I 2 = 0%; 2 studies, 739 participants; high-certainty evidence). Over 120 weeks (initial study period and follow-up), systolic blood pressure rose by 5.1 mmHg and diastolic blood pressure by 4.1 mmHg with twice-daily 400 mg lumacaftor-ivacaftor (80 participants). The tezacaftor-ivacaftor RCTs did not report these adverse effects. Pulmonary exacerbation rates decreased in pwCF receiving additional therapies to ivacaftor compared to placebo (all moderate-certainty evidence): lumacaftor 600 mg (hazard ratio (HR) 0.70, 95% CI 0.57 to 0.87; I 2 = 0%; 2 studies, 739 participants); lumacaftor 400 mg (HR 0.61, 95% CI 0.49 to 0.76; I 2 = 0%; 2 studies, 740 participants); and tezacaftor (HR 0.64, 95% CI 0.46 to 0.89; 1 study, 506 participants). Triple therapy No study reported any deaths (high-certainty evidence). All other evidence was low- to moderate-certainty. QoL respiratory domain scores probably improved with triple therapy compared to control at six months (six studies). There was probably a greater relative and absolute change in FEV 1 % predicted with triple therapy (four studies each across all combinations). The absolute change in FEV 1 % predicted was probably greater for F508del/MF participants taking elexacaftor-tezacaftor-ivacaftor compared to placebo (mean difference 14.30, 95% CI 12.76 to 15.84; 1 study, 403 participants; moderate-certainty evidence), with similar results for other drug combinations and genotypes. There was little or no difference in adverse events between triple therapy and control (10 studies). No study reported time to next pulmonary exacerbation, but fewer F508del/F508del participants experienced a pulmonary exacerbation with elexacaftor-tezacaftor-ivacaftor at four weeks (OR 0.17, 99% CI 0.06 to 0.45; 1 study, 175 participants) and 24 weeks (OR 0.29, 95% CI 0.14 to 0.60; 1 study, 405 participants); similar results were seen across other triple therapy and genotype combinations.
Authors' Conclusions: There is insufficient evidence of clinically important effects from corrector monotherapy in pwCF with F508del/F508del. Additional data in this review reduced the evidence for efficacy of dual therapy; these agents can no longer be considered as standard therapy. Their use may be appropriate in exceptional circumstances (e.g. if triple therapy is not tolerated or due to age). Both dual therapies (lumacaftor-ivacaftor, tezacaftor-ivacaftor) result in similar small improvements in QoL and respiratory function with lower pulmonary exacerbation rates. While the effect sizes for QoL and FEV 1 still favour treatment, they have reduced compared to our previous findings. Lumacaftor-ivacaftor was associated with an increase in early transient shortness of breath and longer-term increases in blood pressure (not observed for tezacaftor-ivacaftor). Tezacaftor-ivacaftor has a better safety profile, although data are lacking in children under 12 years. In this population, lumacaftor-ivacaftor had an important impact on respiratory function with no apparent immediate safety concerns, but this should be balanced against the blood pressure increase and shortness of breath seen in longer-term adult data when considering lumacaftor-ivacaftor. Data from triple therapy trials demonstrate improvements in several key outcomes, including FEV 1 and QoL. There is probably little or no difference in adverse events for triple therapy (elexacaftor-tezacaftor-ivacaftor/deutivacaftor; VX-659-tezacaftor-ivacaftor/deutivacaftor; VX-440-tezacaftor-ivacaftor; VX-152-tezacaftor-ivacaftor) in pwCF with one or two F508del variants aged 12 years or older (moderate-certainty evidence). Further RCTs are required in children under 12 years and those with more severe lung disease.
(Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.)
التعليقات: Update of: Cochrane Database Syst Rev. 2020 Dec 17;12:CD010966. doi: 10.1002/14651858.CD010966.pub3. (PMID: 33331662)
References: Trends Pharmacol Sci. 2007 Jul;28(7):334-41. (PMID: 17573123)
J Cyst Fibros. 2021 Sep;20(5):761-767. (PMID: 33249003)
Lancet Respir Med. 2017 Feb;5(2):107-118. (PMID: 28011037)
Lancet. 2019 Nov 23;394(10212):1940-1948. (PMID: 31679946)
Lancet Respir Med. 2021 Jul;9(7):721-732. (PMID: 33516285)
Mol Ther. 2002 Jul;6(1):119-26. (PMID: 12095312)
Am J Respir Crit Care Med. 1998 Feb;157(2):484-90. (PMID: 9476862)
N Engl J Med. 2021 Aug 26;385(9):815-825. (PMID: 34437784)
Proc Natl Acad Sci U S A. 2011 Nov 15;108(46):18843-8. (PMID: 21976485)
Stat Med. 1998 Dec 30;17(24):2815-34. (PMID: 9921604)
J Cyst Fibros. 2019 Sep;18(5):737-742. (PMID: 30587335)
Pediatr Pulmonol. 2002 Feb;33(2):142-50. (PMID: 11802252)
Science. 1989 Sep 8;245(4922):1066-73. (PMID: 2475911)
J Cyst Fibros. 2021 Mar;20(2):228-233. (PMID: 32586736)
Cochrane Database Syst Rev. 2018 Aug 02;8:CD010966. (PMID: 30070364)
Cochrane Database Syst Rev. 2019 Jan 07;1:CD009841. (PMID: 30616300)
Lancet Respir Med. 2014 Jul;2(7):527-38. (PMID: 24973281)
J Cyst Fibros. 2022 May;21(3):529-536. (PMID: 34961705)
N Engl J Med. 2018 Oct 25;379(17):1612-1620. (PMID: 30334692)
N Engl J Med. 2015 Jul 16;373(3):220-31. (PMID: 25981758)
Front Pharmacol. 2022 Mar 14;13:863280. (PMID: 35359862)
J Cyst Fibros. 2021 Nov;20(6):1018-1025. (PMID: 34419414)
Adv Ther. 2019 Feb;36(2):451-461. (PMID: 30554331)
Hum Mutat. 2002 Jun;19(6):575-606. (PMID: 12007216)
Lancet Respir Med. 2022 Mar;10(3):267-277. (PMID: 34942085)
J Cyst Fibros. 2021 Jan;20(1):68-77. (PMID: 32967799)
J Cyst Fibros. 2017 May;16(3):371-379. (PMID: 28209466)
J Cyst Fibros. 2012 May;11(3):231-6. (PMID: 22281182)
Cochrane Database Syst Rev. 2020 Dec 17;12:CD010966. (PMID: 33331662)
J Cyst Fibros. 2021 Mar;20(2):234-242. (PMID: 33339768)
Lancet Respir Med. 2017 Jul;5(7):557-567. (PMID: 28606620)
J Clin Invest. 1997 Nov 15;100(10):2457-65. (PMID: 9366560)
Pharmaceutics. 2020 Nov 12;12(11):. (PMID: 33198319)
N Engl J Med. 2017 Nov 23;377(21):2013-2023. (PMID: 29099344)
J Cyst Fibros. 2021 May;20(3):499-505. (PMID: 33358691)
Stat Med. 2002 Nov 30;21(22):3337-51. (PMID: 12407676)
Cochrane Database Syst Rev. 2023 Mar 3;3:CD012040. (PMID: 36866921)
N Engl J Med. 2011 Nov 3;365(18):1663-72. (PMID: 22047557)
Ann Am Thorac Soc. 2017 Feb;14(2):213-219. (PMID: 27898234)
J Cyst Fibros. 2019 Jan;18(1):94-101. (PMID: 30146268)
Chest. 2011 Jun;139(6):1480-1490. (PMID: 21652558)
N Engl J Med. 2018 Oct 25;379(17):1599-1611. (PMID: 30334693)
Ann Hum Genet. 2003 Sep;67(Pt 5):471-85. (PMID: 12940920)
Lancet Respir Med. 2016 Aug;4(8):617-626. (PMID: 27298017)
Chest. 2009 Jun;135(6):1610-1618. (PMID: 19447923)
N Engl J Med. 2017 Nov 23;377(21):2024-2035. (PMID: 29099333)
Respiration. 2007;74(3):241-51. (PMID: 17534127)
J Cyst Fibros. 2020 Mar;19(2):292-298. (PMID: 31594690)
Thorax. 2012 Jan;67(1):12-8. (PMID: 21825083)
Am J Respir Crit Care Med. 2018 Jan 15;197(2):214-224. (PMID: 28930490)
Nat Genet. 1995 Aug;10(4):445-52. (PMID: 7545494)
Arch Dis Child. 1997 Mar;76(3):278-82. (PMID: 9135274)
J Cyst Fibros. 2019 Sep;18(5):700-707. (PMID: 31056441)
Lancet Respir Med. 2023 Jun;11(6):550-562. (PMID: 36842446)
J Cyst Fibros. 2021 Jan;20(1):78-85. (PMID: 33011099)
N Engl J Med. 2019 Nov 7;381(19):1809-1819. (PMID: 31697873)
J Cyst Fibros. 2020 Nov;19(6):962-968. (PMID: 32546431)
Pediatr Pulmonol. 2002 Feb;33(2):90-8. (PMID: 11802244)
BMJ. 2003 Sep 6;327(7414):557-60. (PMID: 12958120)
سلسلة جزيئية: ClinicalTrials.gov NCT01225211; NCT00865904; NCT03029455; NCT03224351; NCT03559062; NCT01746784; NCT03093714; NCT03227471; NCT00004428; NCT03525444; NCT01931839; NCT02514473; NCT00590538; NCT04105972; NCT01807923; NCT01807949; NCT00016744; NCT01897233; NCT00742092; NCT00945347; NCT01899105; NCT03447262; NCT03525574; NCT03537651; NCT03601637; NCT03633526; NCT03691779; NCT04043806; NCT04058366; NCT04183790; NCT04235140; NCT04362761; NCT04537793; NCT04545515; NCT02392234; NCT03045523; NCT05033080; NCT05076149
المشرفين على المادة: EGP8L81APK (lumacaftor)
126880-72-6 (Cystic Fibrosis Transmembrane Conductance Regulator)
1Y740ILL1Z (ivacaftor)
9A4381183B (VX)
0 (Aminophenols)
0 (CFTR protein, human)
تواريخ الأحداث: Date Created: 20231120 Date Completed: 20231127 Latest Revision: 20240820
رمز التحديث: 20240820
مُعرف محوري في PubMed: PMC10659105
DOI: 10.1002/14651858.CD010966.pub4
PMID: 37983082
قاعدة البيانات: MEDLINE
الوصف
تدمد:1469-493X
DOI:10.1002/14651858.CD010966.pub4